Dosimetric analysis of 17 cardiac Sub-structures, Toxicity, and survival in ultra central lung tumor patients treated with SBRT
Maiwand Ahmadsei(University Hospital of Zurich), Matthias Gückenberger(University of Zurich), Bertrand Pouymayou(University of Zurich), Boldizsar Kovacs(University of Bern), Ardan M. Saguner(Zurich Heart House), Sebastian M. Christ(University of Zurich), Nicolaus Andratschke(University Hospital of Zurich), Panagiotis Balermpas(Goethe University Frankfurt), K. Thaler(University of Zurich), Jonas Willmann(University of North Texas), Michael Mayinger(University Hospital of Zurich), Riccardo Dal Bello(University Hospital of Zurich), Elena Gasser(University of Zurich), Stephanie Tanadini‐Lang(University of Zurich)
Cited by 7
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577